Three new prescription diet drugs for the obese on FDA roadmap

October 22, 2009

(ChattahBox) — Three companies each have a weight-loss drug in the final stages of development, and the race is on to get their drug applications into the FDA for review. Obesity researchers say the drugs by companies Vivus, Arena Pharmaceuticals, and Orexigen, which will not be available to the public for at least a year, could help curb weight-related diseases such as diabetes, heart disease, stroke, and some cancers. Those 30 pounds or more over a healthy weight, who took one of the medications lost about 15 percent of their starting weight in a year, when combined with cutting calories and exercising.

Qnexa from Vivus: Incorporates low doses of two previously approved prescription medications:  phentermine, and topiramate. Phentermine reduces appetite; topiramate increases the sense of fullness.

Lorcaserin hydrochloride from Arena Pharmaceuticals: works on brain chemistry to induce a sense of fullness.

Contrave from Orexigen: combines two drugs,  bupropion, an antidepressant and smoking cessation medication, and naltrexone, currently used for alcohol and opioid addiction. It works to fight food cravings and improves the ability to control eating.

More at USA Today


One Response to “Three new prescription diet drugs for the obese on FDA roadmap”

  1. jason on October 22nd, 2009 6:26 pm

    seriously, isn’t it the fda who got america into their obese habits through FDA approved fast food restaurants?

    why take 1 yr to lose 15 lbs when you can easily lose 20 lbs in 2 1/2 weeks! Look great for the Holidays.

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of - Comments are the opinions of the individuals leaving them, and not of or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.